12 results about "Levetiracetam" patented technology

A high-quality (RS)-α-ethyl-2-oxo-1-pyrrolidine acetic acid acquired by racemization recovery is provided. A method provided significantly increases the quality and appearance of the product (RS)-α-ethyl-2-oxo-1-pyrrolidine acetic acid recovered using racemization and does not affect the product yield.

The invention relates to a method for detecting antiepileptic drugs in serum based on polarity conversion UPLC-MS / MS. The antiepileptic drugs (AEDs) are respectively levetiracetam, pregabalin, gabapentin, lamotrigine, phenobarbital, oxcarbazepine, phenytoin sodium, carbamazepine, clonazepam, diazepam and sodium valproate. Simplifying sample pretreatment by adopting a methanol (containing formic acid) one-step extraction method; in the chromatographic analysis, C18 is used as a chromatographic column and a pre-column, a 5% methanol aqueous solution (containing formic acid)-95% methanol aqueous solution (containing formic acid) is used as a mobile phase, gradient elution is carried out, and the mass spectrum adopts an MRM mode. The method has the advantages of being high in sensitivity, good in precision and accuracy, easy to operate, free of matrix interference and the like, can be used for measuring serum AEDs of different species, and provides technical support for the prevention and treatment mechanism of epilepsy drugs, clinical AEDs blood concentration monitoring, individualized drug delivery scheme formulation and pharmacokinetic research.

The invention belongs to the technical field of drug research, and particularly relates to application of levetiracetam in preparation of drugs for reversing PD-1 inhibitor drug resistance or treating breast cancer. Tests prove that levetiracetam can remodel a tumor immune microenvironment and activate anti-tumor immunity to achieve the effect of treating breast cancer, reverse PD-1 inhibitor drug resistance, inhibit the growth of PD-1 inhibitor drug-resistant cancers and further improve the clinical remission rate of PD-1 inhibitor treatment.

The present invention relates to methods of preventing or slowing the progression of cognitive impairment or preventing the development of cognitive decline or reducing the rate of cognitive decline in a subject exhibiting or exhibiting cognitive performance within a normal range of age of the subject. The method comprises administering to the subject one or more levetiracetam, briracetam, or cetriracetam, or a pharmaceutically acceptable salt thereof, a pharmaceutical composition comprising levetiracetam, briracetam, or cetriracetam, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, the invention relates to a GABAA alpha 5 receptor agonist or a pharmaceutically acceptable salt, a hydrate, a solvate, an isomer or a polymorph of the GABAA alpha 5 receptor agonist, and a pharmaceutical composition containing the GABAA alpha 5 receptor agonist or the pharmaceutically acceptable salt, the hydrate, the solvate, the isomer or the polymorph of the GABAA alpha 5 receptor agonist and a pharmaceutically acceptable carrier. Or a combination or composition comprising levetiracetam, briracetam or setriracetam, or a pharmaceutically acceptable salt thereof, and a GABAA alpha5 receptor agonist, or a pharmaceutically acceptable salt, hydrate, solvate, isomer or polymorphic substance thereof. In some embodiments, the subject has one or more risk factors that are predicted or related to the onset or progression of cognitive impairment or decline.

The present invention relates to the field of pharmaceutical chemical engineering, in particular to a method for purifying a levetiracetam intermediate, which comprises the following steps: (1) hydrolyzing and acidifying a crude product of a compound of formula III and performing crystallization to obtain a compound of formula IV; and (2) subjecting the compound of formula IV to an esterification reaction and separation to obtain a purified compound of formula III. The present method has a purification effect obviously superior to that of a physical purification mode, can reach a total yield of 90% or above, and has a great practical value.

A method of intranasal drug delivery including administering a multi-compartment nanoemulsion to a nasal cavity of a subject in need thereof, where the multi-compartment nanoemulsion includes a water-in-oil core emulsion having an oil phase encompassing a first aqueous phase, the oil phase comprising a first surfactant and a fatty acid and the first aqueous phase comprising levetiracetam and valproic acid dissolved therein. The multi-compartment nanoemulsion further includes a second aqueous phase encompassing the water-in-oil core emulsion, the second aqueous phase comprising a second surfactant and a co-surfactant in a ratio of the second surfactant to the co-surfactant of 1:4 to 4:1. The multi-compartment nanoemulsion has an average droplet size of less than 100 nm and a polydispersity index (PDI) of 0.1 to 0.2.

The present invention relates to the field of pharmaceutical chemical engineering, in particular to a method for purifying a levetiracetam intermediate, which comprises the following steps: (1) hydrolyzing and acidifying a crude product of a compound of formula III and performing crystallization to obtain a compound of formula IV; and (2) subjecting the compound of formula IV to an esterification reaction and separation to obtain a purified compound of formula III. The present method has a purification effect obviously superior to that of a physical purification mode, can reach a total yield of 90% or above, and has a great practical value.

The present invention relates to a solid pharmaceutical composition manufactured by a wet granulation method comprising levetiracetam or pharmaceutically acceptable salts thereof, at least one or more disintegrant, at least one or more diluent, at least one binder, at least one glidant, at least one lubricant, and one or more pharmaceutically acceptable excipients. The orodispersible tablet prepared using these excipients exhibits desirable properties such as facilitating disintegration, and dissolution of the drug for oral administration. Further, the present invention also relates to the process for preparing the said solid pharmaceutical composition.

Levetiracetam is described for use in the treatment of hydrocephalus and the pain caused by it.

The utility model relates to tableting drying technical field, concretely relates to a kind of levetiracetam tabletting drying equipment, including hopper, discharging assembly, tableting assembly and drying assembly;Discharging assembly, be arranged in the below of the hopper, for the levetiracetam tablet powder falling inside the hopper above and pass to the tableting assembly below;Tableting assembly, be arranged in the below of the discharging assembly, for the tablet powder falling of discharging assembly above and powder are quantitatively distributed while being pressed into tablet;Drying assembly, be arranged in the below of the tableting assembly, for the levetiracetam tablet of pressing into shape and carry out drying work.Just compared with prior art, the present application solves the problem of uneven powder material discharging and powder accumulation in the tabletting process in the prior art.

The invention provides a concentration determination kit for five anti-epileptic drugs, the kit is used for detecting the anti-epileptic drugs in a serum sample by liquid chromatography-tandem mass spectrometry, the kit comprises a diluent, an internal standard solution IS, a plurality of calibration products and a plurality of quality control products, and the calibration products and the quality control products are freeze-dried preparations. The kit provided by the invention can be used for detecting that the linearity range of clonazepam is 4-200ng / mL, the linearity range of valproic acid is 3-150mu g / mL, the linearity range of 10, 11-dihydro-10-hydroxycarbamazepine is 0.8-40mu g / mL, the linearity range of levetiracetam is 1.0-50mu g / mL, the linearity range of topiramate is 0.5-25mu g / mL, the correlation coefficient r is not less than 0.9900, and the detection result is accurate and reliable. The in-batch variation coefficient CV is not greater than 15.0%, the inter-batch variation coefficient CV is not greater than 15.0%, and the kit is good in consistency and high in stability. The accurate recovery rate is in a range of 85.0%-115.0%, and the detection result is accurate. The quantitative limit CV is smaller than or equal to 20%, the relative deviation is within the range of + / -15%, and the kit is high in sensitivity and has high repeatability and reliability. The product can be stably stored for 12 months at 2-8 DEG C, and the shelf life is long.